ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Locoregional Therapy for Hepatocellular Carcinoma Decreases Liver Transplant Waitlist Dropout and Mortality

S. Weeks, T. Ishaque, A. Massie, D. Segev, E. King

Johns Hopkins, Baltimore, MD

Meeting: 2022 American Transplant Congress

Abstract number: 1091

Keywords: Hepatocellular carcinoma, Liver, Liver transplantation

Topic: Clinical Science » Liver » 56 - Liver: Hepatocellular Carcinoma and Other Malignancies

Session Information

Session Name: Liver: Hepatocellular Carcinoma and Other Malignancies

Session Type: Poster Abstract

Date: Sunday, June 5, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Liver transplant candidates with hepatocellular carcinoma (HCC) risk tumor progression that may disqualify them from transplant eligibility while awaiting HCC exception points on the waitlist. Most centers therefore perform locoregional therapy (LRT) with chemoembolization and/or radiofrequency ablation as a bridge to transplant. Use of LRT to prevent tumor progression and enable eventual transplant is supported by single center studies and consensus guidelines; however, there has been no evaluation of national waitlist outcomes comparing candidates undergoing LRT to those that have not.

*Methods: We used SRTR data to examine adult first time liver transplant candidates with HCC within Milan criteria activated between 1/1/2010 and 5/31/2021 and compared candidates who underwent LRT with to those who did not, stratified by tumor burden at presentation. We used Cox regression models to compare rate of transplant and combined outcome of waitlist mortality and dropout between groups. Models were adjusted for age, race, sex, diagnosis, blood group, insurance, and initial tumor size and type.

*Results: 15796 candidates underwent LRT; 7923 did not. There were no differences between groups in terms of age, sex, or blood group. Candidates receiving LRT were more likely to have a single tumor > 3 cm (26% vs 19%, p<0.001) or multiple tumors (27% vs 23%, p <0.001). There were no differences in transplant rate between groups (Table 1). Candidates undergoing LRT had a lower risk of waitlist mortality/dropout compared to those who did not undergo bridging therapy (Table 2). Stratified by tumor burden, candidates with a single tumor ≤ 3 cm were 11% less likely to die on or drop off the waitlist if they had LRT (95% CI: 0.81-0.89), candidates with a single tumor >3 cm were 21% less likely to die on or drop off the waitlist if they had LRT (95% CI: 0.69-0.90), and there was no difference in waitlist mortality or dropout in candidates with multiple tumors (aHR 0.95; 95% CI 0.83-1.08).

*Conclusions: In this first examination of national SRTR data to examine waitlist outcomes for liver transplant candidates with HCC, we found LRT was associated with decreased waitlist mortality and dropout. Our data suggests the association is largest in candidates with single tumors.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Weeks S, Ishaque T, Massie A, Segev D, King E. Locoregional Therapy for Hepatocellular Carcinoma Decreases Liver Transplant Waitlist Dropout and Mortality [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/locoregional-therapy-for-hepatocellular-carcinoma-decreases-liver-transplant-waitlist-dropout-and-mortality/. Accessed May 8, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences